What happens in the skin? Integrating skin permeation kinetics into studies of developmental and reproductive toxicity following topical exposure.

Reprod Toxicol

Clinical Research Unit for Skin, Allergy and Regeneration & Experimental Dermatology Laboratory, Institute of Medical Biology, A*STAR, Singapore. Electronic address:

Published: December 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Animal-based developmental and reproductive toxicological studies involving skin exposure rarely incorporate information on skin permeation kinetics. For practical reasons, animal studies cannot investigate the many factors which can affect human skin permeation and systemic uptake kinetics in real-life scenarios. Traditional route-to-route extrapolation is based on the same types of experiments and requires assumptions regarding route similarity. Pharmacokinetic modeling based on skin physiology and structure is the most efficient way to incorporate the variety of intrinsic skin and exposure-dependent parameters occurring in clinical and occupational settings into one framework. Physiologically-based pharmacokinetic models enable the integration of available in vivo, in vitro and in silico data to quantitatively predict the kinetics of uptake at the site of interest, as needed for 21st century toxicology and risk assessment. As demonstrated herein, proper interpretation and integration of these data is a multidisciplinary endeavor requiring toxicological, risk assessment, mathematical, pharmaceutical, biological and dermatological expertise.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reprotox.2015.10.001DOI Listing

Publication Analysis

Top Keywords

skin permeation
12
permeation kinetics
8
developmental reproductive
8
risk assessment
8
skin
6
skin? integrating
4
integrating skin
4
kinetics
4
kinetics studies
4
studies developmental
4

Similar Publications

Tyrosinase, a copper-dependent oxidase, plays a critical role in melanin biosynthesis and is a target in skin-whitening cosmetics. Conventional inhibitors like arbutin and kojic acid are widely used but suffer from cytotoxicity, instability, and inconsistent efficacy, highlighting the need for safer, more effective alternatives. In this study, two ligand-based machine learning models were developed: one to predict the biological activity of compounds and the other to estimate specific pIC values.

View Article and Find Full Text PDF

Effect of the combination of ion-pairs strategies and permeation enhancers on iguratimod transdermal patch against rheumatoid arthritis.

Eur J Pharm Biopharm

September 2025

Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, PR China. Electronic address:

Iguratimod (IGU) is a novel anti-rheumatic drug, which has anti-inflammatory effects, inhibits bone destruction, and promotes bone formation. However, the gastrointestinal side-effects caused by oral tablets of IGU pose a challenge. This study aimed to develop an IGU transdermal patch for Rheumatoid Arthritis (RA) through ion-pair and chemical penetrant strategies to improve the therapeutic efficacy.

View Article and Find Full Text PDF

Chronic wounds infected with multidrug-resistant bacteria pose a significant therapeutic challenge, requiring biocompatible and effective interventions. This study presents a novel lignin-based nanoparticle spray for the localized delivery of curcumin, a natural anti-inflammatory and antimicrobial compound. Lignin, a sustainable polyphenolic biopolymer with inherent antioxidant and antimicrobial activities, was used both as a carrier and functional agent.

View Article and Find Full Text PDF

Tuberculosis (TB), caused by , remains a global health emergency, particularly in low- and middle-income countries. Despite effective pharmacotherapy, prolonged treatment, poor adherence, and drug resistance continue to hinder eradication. Isoniazid (ISZ), a first-line antitubercular drug, is effective but limited by high aqueous solubility and short half-life, necessitating daily administration and causing plasma fluctuations.

View Article and Find Full Text PDF

Tadalafil (TDLF), a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and extensive first-pass metabolism, which limits its therapeutic efficacy. We developed Phosal-based transethosomes (TrEthOs) to overcome these challenges, thereby enhancing transdermal delivery. A Box-Behnken design was employed to optimize the formulation by evaluating the effects of Phosal type, polyethylene glycol (PEG) 400 concentration, and cholesterol content.

View Article and Find Full Text PDF